ARK Invest's position in GH, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKG | 647,435 | $100.3M | 5.08% | #5 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-12 | ARKG | Buy | Added | 12,720 | $2.1M |
| 2026-10-09 | ARKG | Buy | Added | 7,210 | $1.2M |
| 2026-09-16 | ARKG | Buy | Added | 7,739 | $1.4M |
| 2026-09-15 | ARKG | Buy | Added | 9,070 | $1.6M |
| 2026-09-14 | ARKG | Buy | Added | 39,558 | $6.6M |
| 2026-08-31 | ARKG | Buy | Added | 56,987 | $9.1M |
| 2026-07-09 | ARKG | Sell | Trimmed | 16,105 | $2.6M |
| 2026-07-08 | ARKG | Sell | Trimmed | 6,344 | $991K |
| 2026-07-07 | ARKG | Sell | Trimmed | 5,602 | $913K |
| 2026-03-20 | ARKG | Sell | Trimmed | 9,621 | $820K |
| 2026-03-18 | ARKG | Sell | Trimmed | 11,757 | $1.0M |
| 2026-02-27 | ARKG | Sell | Trimmed | 27,334 | $2.6M |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect…
See GH's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open GH on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.